“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Dr Tedros Calls For Investment In Nurses, Highlights WHA 2020 Focus On Nurses & Midwives 02/07/2019 David Branigan In a surprise appearance before the 2019 Congress of the International Council of Nurses, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that investing in a stronger nursing workforce is essential for achieving universal health coverage (UHC). He proposed that “every country bring one nurse and one midwife to the World Health Assembly next year,” as […] Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now 25/04/2019 William New Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
Dr Tedros Calls For Investment In Nurses, Highlights WHA 2020 Focus On Nurses & Midwives 02/07/2019 David Branigan In a surprise appearance before the 2019 Congress of the International Council of Nurses, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that investing in a stronger nursing workforce is essential for achieving universal health coverage (UHC). He proposed that “every country bring one nurse and one midwife to the World Health Assembly next year,” as […] Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now 25/04/2019 William New Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now 25/04/2019 William New Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
New Resource Gateway Launched On Innovation & Access To Medicines 14/06/2019 Elaine Ruth Fletcher A new Knowledge Portal that aims to ease policymakers’ access to reliable information about themes in medicines access, pricing and pharma innovation was launched today by the Global Health Centre of Geneva’s Graduate Institute of International and Development Studies. The Portal currently covers some 17 topics grouped under three broad themes – Pricing, Intellectual Property […] Continue reading -> WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now 25/04/2019 William New Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
WHO Report On Cancer Medicines Pricing: Detailed Info On Findings 02/05/2019 David Branigan The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading -> Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now 25/04/2019 William New Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now 25/04/2019 William New Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing 30/01/2019 David Branigan A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs. Continue reading -> WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts
WHO Executive Board Meeting: What Are The Hot Topics? 22/01/2019 Catherine Saez The World Health Organization Executive Board is being asked this week to consider a steep budget increase to cover the ambitious new “Transformation Plan” of Director General Tedros Adhanom Gheyebresus, which aims to improve the health of at least 3 billion people by 2025. The 8 percent budget hike requested for 2020-2021 will be reviewed by the Board along with a range of critical policy issues when it meets for its 144th session from 24 January-1 February. Here's what you need to know to follow the action. Continue reading -> Posts navigation Older postsNewer posts